Detalles de la búsqueda
1.
Consideration of Potential Drug-Drug Interactions in Selection of FDA-Approved Drugs Indicated for Prostate Cancer.
Am J Ther
; 26(3): e422-e424, 2019.
Artículo
en Inglés
| MEDLINE | ID: mdl-30677005
2.
Total cost of care for castration-resistant prostate cancer in a commercially insured population and a medicare supplemental insured population.
J Med Econ
; 23(1): 54-63, 2020 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-31589086
3.
Matching-Adjusted Indirect Comparison of the Efficacy of Apalutamide and Enzalutamide with ADT in the Treatment of Non-Metastatic Castration-Resistant Prostate Cancer.
Adv Ther
; 37(1): 501-511, 2020 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31813086
4.
Medication Adherence, Treatment Patterns, and Dose Reduction in Patients with Metastatic Castration-Resistant Prostate Cancer Receiving Abiraterone Acetate or Enzalutamide.
Am Health Drug Benefits
; 10(6): 296-303, 2017 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-28975013
5.
Assessment of Real-World Central Nervous System Events in Patients with Advanced Prostate Cancer Using Abiraterone Acetate, Bicalutamide, Enzalutamide, or Chemotherapy.
Am Health Drug Benefits
; 10(3): 143-153, 2017 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-28626511
6.
Duration of Treatment in Prostate Cancer Patients Treated with Abiraterone Acetate or Enzalutamide.
J Manag Care Spec Pharm
; 23(2): 225-235, 2017 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-28125362
7.
Assessment of Evidence-Based Standards in the Treatment of Advanced Prostate Cancer in a Community Practice.
Urol Pract
; 4(3): 218-224, 2017 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-37592661
8.
Estimating the Size and Cost of the STD Prevention Services Safety Net.
Public Health Rep
; 130(6): 602-9, 2015.
Artículo
en Inglés
| MEDLINE | ID: mdl-26556931
9.
Comparative efficacy and safety of daclatasvir/asunaprevir versus IFN-based regimens in genotype 1b hepatitis C virus infection.
J Comp Eff Res
; 4(6): 593-605, 2015 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-26159375
10.
Cost-effectiveness analysis of screening for KRAS and BRAF mutations in metastatic colorectal cancer.
J Natl Cancer Inst
; 104(23): 1785-95, 2012 Dec 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-23197490
11.
Community-level incentives to increase the use of vaccination services in developing countries: an idea whose time has come?
Vaccine
; 28(38): 6123-4, 2010 Aug 31.
Artículo
en Inglés
| MEDLINE | ID: mdl-20637772
Resultados
1 -
11
de 11
1
Próxima >
>>